Skip to main content
OpenTrials
Completed

NCT Number: NCT02014324

Single Scope Staging of Lung Cancer With Endosonography

Rationale: Lung cancer is the most commonly diagnosed cancer worldwide and is the most frequent cause of cancer death. Accurate staging is important because it directs treatment and prognosis. Mediastinal staging can be done by both EBUS-TBNA and EUS-FNA. These two techniques have a complementary diagnostic range and the combined procedure is suited for assessment of almost the entire mediastinum. In practice, when mediastinal tissue staging is indicated, endoscopists often perform either an EBUS or an EUS investigation (instead of the combined procedure). Second, frequently only one or two, by imaging suspected lymph node stations, are sampled (ie. targeted approach).

Objectives: main and secondary:

1. Complete endosonographic (combined endobronchial and esophageal) staging using a single EBUS scope improves locoregional staging (N2, N3, T4) versus EBUS staging alone. 2. Systematic mediastinal staging results in improved locoregional staging compared to PET-CT directed assessment of the mediastinum (ie targeted approach).

Study population: Patients with potentially operable and resectable NSCLC are eligible if there is an indication for mediastinal nodal sampling. Patients have an indication for EBUS-TBNA.

Intervention: Patients will undergo an EBUS investigation followed by EUS-B in the same session. During this single scope procedure, lymph nodes that are suspected on prior CT-PET imaging and on subsequent ultrasound are sampled.

Main study endpoint: The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Onze-Lieve-Vrouwen-Ziekenhuis, Aalst, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (Suspected) NSCLC;
  • Indication for mediastinal nodal assessment;
  • Suspected mediastinal lymph nodes within reach of EBUS;
  • Age 18 years or older;
  • Clinically fit to undergo surgical resection of the lung tumor;
  • Provision of a written informed consent;

Exclusion criteria

  • Mediastinal re-staging after neo-adjuvant treatment;
  • Indication for EUS other than mediastinal staging, eg a for malignancy
  • suspected left adrenal;
  • Active malignancy with a life expectancy of less than two years;
  • Former therapy for lung cancer (chemotherapy, radiotherapy or surgery);
  • Technical contraindication for EBUS or EUS (eg, esophagus stenosis);
  • Pregnancy;
  • Inability to consent;

Treatment and study plan

Endosonography

Procedure

Complete endosonographic mediastinal staging is performed in 2 steps:

  • Systematic EBUS (airways)
  • Systematic EUS-B (esophagus)

Other names: EBUS, EUS-B

Primary outcomes

  1. Sensitivity for locoregional disease (N2, N3, T4 disease).

    Time frame: from inclusion untill either pathological proof of mediastinal metastases by endospnography or 1 week after surgical verification

    Sensitivity is defined as number of true positives (pathologic proof of a nodal metastases) divided by the number of true positives and false negatives (thoracotomy with nodal dissection is the reference standard to detect false negatives).

    The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.

    In the event of pathological proof of mediastinal metastases (N2/N3) by endosonography patients are classified as having locally advanced disease (stage III) and the study stops. When no mediastinal metastases are found by endosonography, surgical verification will take place (reference standard).

Secondary outcomes

  1. Sensitivity for locally advanced disease (N2-3 metastases, T4). Systematic assessment and sampling of mediastinal lymph nodes versus PET-CT directed assessment of the mediastinum.

    Time frame: from inclusion untill either pathological proof of mediastinal metastases by endosonography or 1 week after surgical verification

    Sensitivity for locally advanced disease (N2-3 metastases, T4) of systematic assessment and sampling of mediastinal lymph nodes in comparison to PET-CT directed assessment of the mediastinum (ie targeted approach).

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Registry information

Official study title

Complete Endosonographic Staging of Lung Cancer: a Systematic Single Scope Approach

Acronym: SCORE

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Dec 18, 2013
Registry last updated
Oct 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.